Could a One-Time X-Ray calm the deadly lung inflammation of severe COVID-19?

NCT ID NCT04427566

Stopped early, before it reached the end. That can be for many reasons, including safety.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This phase II trial tests whether a single, ultra-low dose of radiation to both lungs can reduce the dangerous inflammation caused by COVID-19 pneumonia in critically ill patients who need a ventilator. The treatment, a one-time 80 cGy X-ray session, aims to calm the immune system's overreaction in the lungs, potentially helping patients breathe on their own. The study will measure mortality and hospital stay durations to see if this old technique, once used for pneumonia, might offer a new tool against severe COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ultra low-dose bilateral whole lung radiation therapy (a single 80 cGy dose of X-rays to both lungs)
What this could lead to
If effective, this could offer a quick, one-time treatment to reduce lung inflammation in severe COVID-19, potentially helping patients breathe without a ventilator and lowering mortality.
What could go wrong
This is a very small early-phase study (only 2 participants), so results may not be conclusive. Radiation to the lungs carries risks, and the benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

2 people

The number who actually took part.

Started

Jul 2020

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Laboratory Diagnosis of COVID-19 based within 14 days of enrollment. * CT or radiographic findings typical of COVID-19 pneumonia within 5 days of enrollment * Receiving ICU-based mechanical ventilation * Life expectancy ≥ 24 hours, as judged by investigator * Hypoxemia defined as a Pa/FIO2 ratio \< 300 or SpO2/FiO2 \< 315 * Signed informed consent by patient or his or her legal/authorized representative Exclusion Criteria: * Moribund with survival expected \< 24 hours, as judged by investigator and treating team * Expected survival \< 30 days, as judged by investigator and treating team, due to chronic illness present prior to COVID infection * Patient or legal representative not committed to full disease specific therapy, i.e. comfort care (DNRCCA is allowed) * Treatment with immune suppressing medications in the last 30 days (steroids for acute respiratory distress syndrome or septic shock allowed) * Presumed COVID-associated illness greater than 14-days * Inpatient admission greater than 14-days * Patient deemed unsafe for travel for radiation therapy * Chronic hypoxemia requiring supplemental oxygen at baseline * Documented active connective tissue disease (scleroderma) or idiopathic pulmonary fibrosis * History of prior radiation therapy resulting in ≥grade 2 radiation pneumonitis within 365 days of enrollment * Active or history of prior radiation to the thorax completed within 180 days of enrollment (skin or surface only skin treatments are acceptable) * Known active uncontrolled bacterial or fungal infections of the lung. * Active cytotoxic chemotherapy * Females who are pregnant or have a positive pregnancy test * Breast feeding * Note: concurrent administration of convalescent immune plasma therapy either on clinical trial or as a standard therapy not an exclusion criterion, but will be noted

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.